Tag: Bamlanivimab

FDA, Regulations

FDA grants emergency authorisation to Lilly’s COVID-19 antibody

November 11, 2020

Via: Pharma Times

Bamlanivimab is now available under emergency use for the treatment of mild to moderate COVID-19 in adults and paediatric patients 12 years and older who are at high risk of progressing to severe COVID-19 and/or hospitalisation. In a statement, Lilly […]